293 cell transfection for rAAV production using the Calcium phosphate transfection Kit

rAAV was produced into 293 cells (70% confluence) using the Calcium Phosphate transfection Kit 

this patent uses the high production capacity of the Calcium Phosphate kit from OZ Biosciences to produce rAAV in 293 cells.

patent reference: United States Patent Application 20130096182

RECOMBINANT ADENO-ASSOCIATED VECTORS FOR TARGETED TREATMENT 
Chatterjee, Saswati (Altadena, CA, US)
Smith, Laura (Pasadena, CA, US)
Wong, Kamehameha (Altadena, CA, US) 

Abstract:

Novel adeno-associated virus (AAV) vectors in nucleotide and amino acid forms and uses thereof are provided. The isolates show specific tropism for certain target tissues, such as blood stem cells, liver, heart and joint tissue, and may be used to transduce stem cells for introduction of genes of interest into the target tissues. Certain of the vectors are able to cross tightly controlled biological junctions, such as the blood-brain barrier, which open up additional novel uses and target organs for the vectors, providing for additional methods of gene therapy and drug delivery.

Calcium Phosphate transfection Kit is perfect to transfect HEK 293 cells. This transfection method, first described by Graham and Van Der Ebb in 1973, has been optimized in order to reach higher transfection efficiency. The CaPO transfection kit from OZ Biosciences is simple and easy to use. It allows reaching between 95 and 100% of HEK 293 transfected cells and a very high titer for virus production.